Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAllison M. BockACAmrita ChauhanLFLorenzo Falchi

Discussion

Loading...

Member takes

Overview

Multicenter retrospective study reveals clinical factors impacting progression free survival in R/R B-cell lymphoma patients receiving epcoritamab, indicating need for tailored therapy.

Key Points

  • This research evaluates prognostic factors impacting survival outcomes in patients with R/R LBCL treated with epcoritamab.
  • Multicenter retrospective study of adult patients with R/R LBCL treated with epcoritamab outside clinical trials.
  • Patients received treatment between 2023 and 2025 at 11 centers in the CUBIC consortium.
  • Survival outcomes like overall response, complete response, progression free survival, and overall survival were calculated using Kaplan Meier method.
  • Overall response rate was 48.7% and complete response rate was 30.8%.
  • Median progression free survival was 3.6 months and median overall survival was 6.2 months.
  • Trial ineligible patients exhibited significantly inferior survival outcomes compared to trial eligible patients.

Cite This Study

Bock et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236deefhttps://doi.org/10.1182/blood-2025-3739
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab2026
  2. 2Effectiveness of epcoritamab in a heterogeneous population with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) including post-chimeric antigen receptor T-cell therapy (CAR T) patients: Insights from the real-world epcoritamab patient characteristics and outcomes research (Real-EPCOR) study2025
  3. 3Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations2025
  4. 4Multicenter, randomized phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy (CAR-T).2024 · 3 citations
  5. 5Multicenter, randomized Phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy: Trial in progress2025